Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya Disease (NCT04917003) | Clinical Trial Compass
UnknownNot Applicable
Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya Disease
China60 participantsStarted 2021-06-15
Plain-language summary
Encephaloduroarteriosynangiosis (EDAS) is widely used as an indirect technique for treatment of moyamoya disease. Nevertheless, this indirect surgery tends to establish insufficient collateral circulation in most adult MMD patients. Nowadays, there is a lack of adjuvant therapies for improving collateral circulation induced by indirect revascularization. This study aims to explore whether remote ischemic conditioning can improve the collateral circulation after indirect revascularization.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subjects who were diagnosed as moyamoya disease by the diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012.
✓. Suzuki stage: 2-5 stage
✓. Age: between 18 and 65 years old
✓. Subjects present with ischemic stroke or transient ischemic attack.
✓. Subjects who plan to accept the first EDAS surgery.
✓. Informed consent obtained from patient or patient's surrogate
Exclusion criteria
✕. Acute ischemic stroke occurred within one month.
✕. Suffered Intracranial hemorrhage before
✕. Subjects with large infarction spread widely over the territory of a main arterial trunk
✕. Aneurysms in the main arterial trunk
✕. Severe cardiac diseases like atrial fibrillation，valvular disease，heart failure, infective endocarditis and so on.
✕. Malignant tumors or severe disordered function of the heart, lung, liver or kidney.
✕. Severe hemostatic disorder or severe coagulation dysfunction.
. Uncontrolled diabetes mellitus with a serum fasting blood glucose level\>300 mg/dL, or requires insulin; hypertension with a systolic blood pressure over 180 mmHg or a diastolic blood pressure over 110 mmHg.